Pfizer (NYSE:PFE) Trading 1.5% Higher – Should You Buy?

Pfizer Inc. (NYSE:PFE)’s share price traded up 1.5% during trading on Tuesday . The stock traded as high as $25.51 and last traded at $25.45. 66,305,132 shares changed hands during trading, an increase of 29% from the average session volume of 51,441,383 shares. The stock had previously closed at $25.08.

Analyst Ratings Changes

A number of research firms recently issued reports on PFE. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. UBS Group reissued a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, Bank of America upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $28.28.

Pfizer Price Performance

The stock has a market cap of $144.70 billion, a P/E ratio of 13.54, a P/E/G ratio of 0.81 and a beta of 0.54. The business has a 50 day simple moving average of $24.81 and a 200-day simple moving average of $24.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is presently 100.00%.

Hedge Funds Weigh In On Pfizer

A number of large investors have recently modified their holdings of PFE. Westbourne Investments Inc. bought a new stake in Pfizer in the first quarter worth $2,411,000. Bourne Lent Asset Management Inc. increased its holdings in shares of Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after buying an additional 18,200 shares during the period. Strs Ohio purchased a new position in shares of Pfizer in the first quarter worth about $49,968,000. IFM Investors Pty Ltd lifted its stake in shares of Pfizer by 3.8% in the 2nd quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock valued at $27,322,000 after acquiring an additional 41,263 shares during the last quarter. Finally, Intrua Financial LLC boosted its holdings in Pfizer by 17.4% during the 1st quarter. Intrua Financial LLC now owns 78,392 shares of the biopharmaceutical company’s stock valued at $1,986,000 after acquiring an additional 11,643 shares during the period. 68.36% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.